The Dow Chemical Company

Phyton Holdings, LLC

W H Kerr Anderson

Philip Ronald Tempest

William Joseph Harris

Frank J Carr

Kathryn Armour

Mark W Rixon

Peter S Mezes

Brian B Gourlie

Jeffrey Schlom

Andrew C Hiatt

Joseph F Petolino

Dayakar Reddy Pareddy

Mich B Hein

Donald A Kaplan

Beth C Rubin-Wilson

Kristen Briggs

Jean L Roberts

Anton S Karnoup

Doug Taylor

Todd Glancy

This invention provides for the plant production of immunoglobulins, wherein at least a portion of the glycans attached to the immunoglobulins lack fucose. The invention also provides the constructs; plasmids; vectors; transformed plant cells, transformed plant calli; transformed plant tissues (e.g., leaves, seeds, tubers, etc.); transformed whole plants used to produce such immunoglobulins; methods of producing the immunoglobulins; the immunoglobulins produced by the disclosed methods; and the use of such immunoglobulins.

Plant production of immunoglobulins with reduced fucosylation

Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.

High affinity humanized anti-TAG-72 monoclonal antibodies

High affinity humanized anti-Tag-72 monoclonal antibodies

High affinity humanized anti-tag-72 monoclonalantibodies

This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V and V sequences which mediate TAG-72 binding and (2) human C and C regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C and C antibody domains. The nucleotide and amino acid sequences of V &agr;TAG V , CC46 V , CC49V , CC83 V , and CC92 V , and CC49V , CC83 V , and CC92 V idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.

Probing method for identifying antibodies specific for selected antigens

Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.

High affinity humanized anti-CEA monoclonal antibodies

High affinity humanized anti-TAG-72 monoclonalantibodies

This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V,and V,sequences which mediate TAG-72 binding and (2) human C,and C,regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C,and C,antibody domains. The nucleotide and amino acid sequences of V,&agr;TAG V,, CC46 V,, CC49,, CC83 V,, and CC92 V,, and CC49,, CC83 V,, and CC92 V,idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.

Family of high affinity, modified antibodies for cancer treatment

Growing community of inventors

Midland, MI, United States of America

W H Kerr Anderson